Achillion Pharmaceuticals

Newsroom

Discover our latest news

November 14, 2017:
Achillion Announces Proposed Secondary Offering of Common Stock

November 14, 2017:
Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G

November 06, 2017:
Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

DOWNLOADS ON DEMAND

COMPLEMENT SYMPOSIUM HOSTED BY ACHILLION

Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, provided the opening remarks at the first Complement Symposium, hosted by Achillion, which was held in Orlando, Florida during the American Society of Hematology 2015 Annual Meeting,
December 6, 2015.

Dr. Peter Densen, M.D., Professor of Internal Medicine – Infectious Disease, University of Iowa, provided a detailed look at the role of thecomplement system and the relative risks of infection associated with immune modulation.

Dr. Scott Barnum, Ph.D., Department of Microbiology at the University of Alabama at Birmingham, presented a review of complement immune-biology and the roles of the classical, lectin, and alternative pathways.

Dr. David Apelian, M.D., Ph.D., Chief Medical Officer of Achillion Pharmaceuticals, discussing the nomination of ACH-4471, small-molecule complement factor D inhibitor, being developed for the treatment of ultra-rare diseases,
including PNH.